Stock Financial Ratios, Dividends, Split History

CHEF / Chefs' Warehouse, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)655.59
Enterprise Value ($M)942.34
Book Value ($M)248.59
Book Value / Share8.66
Price / Book2.63
NCAV ($M)-142.38
NCAV / Share-4.96
Price / NCAV-5.68
Share Statistics
Weighted Average Number Of Diluted Shares Outstanding 27,424,526
Preferred Stock Shares Outstanding 0
Common Shares Outstanding 28,441,253
Common Stock Shares Outstanding 28,442,208
Weighted Average Number Diluted Shares Outstanding Adjustment 68,670
Weighted Average Number Of Shares Outstanding Basic 26,118,482
Scoring Models
Piotroski F-Score6.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.02
Return on Assets (ROA)0.02
Return on Equity (ROE)0.07
Balance Sheet (mrq) ($M)
Quick Ratio1.87
Current Ratio2.88
Income Statement (mra) ($M)
Operating Income41.13
Net Income14.37
Earnings Per Share Basic0.55
Earnings Per Share Diluted0.54
Cash Flow Statement (mra) ($M)
Cash From Operations31.50
Cash from Investing-42.41
Cash from Financing-42.41
Identifiers and Descriptors
Central Index Key (CIK)1517175

Split History

Stock splits are used by Chefs' Warehouse, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

21h - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Related News Stories

CHEF vs. MGPI: Which Stock Is the Better Value Option?

11h zacks
Investors interested in Food - Miscellaneous stocks are likely familiar with Chefs' Warehouse (CHEF - Free Report) and MGP (MGPI - Free Report) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look. (3-0)

Dean Foods Gains 15% in 3 Months: Can the Upside Continue?

12h zacks
Dean Foods Company (DF - Free Report) has seen its stock revive of late, with its shares up 14.5% in the past three months, outperforming the industry’s 12% growth. This Zacks Rank #3 (Hold) company, which was otherwise down 11.8% in the past six months and 42.1% in the past year, seems to be recovering on the back of its better-than-expected first-quarter 2018 results. Let’s delve deeper and see if Dean Foods’ growth drivers can help sustain this momentum amid volume-related hurdles. (15-1)

Stocks To Watch: Don't Sleep On Vienna

2018-06-16 seekingalpha
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. (526-2)

Will Travel Retail, Online Continue to Drive Estee Lauder?

2018-06-15 zacks
The Estee Lauder Companies Inc. (EL - Free Report) has been mainly riding on buyouts, solid online growth and strong travel retail network. These factors, which have been fueling the company’s stellar earnings surprise record, are likely to continue driving its ongoing performance. Though the company has been battling sluggish retail traffic in the U.S. brick-and-mortar stores, it looks like the aforementioned upsides will help the cosmetics biggie sustain the robust momentum. (9-0)

Conagra's (CAG) Growth Prospects Bright Amid Margin Pressure

2018-06-15 zacks
On Jun 15, we issued an updated research report on premium consumer goods company Conagra Brands, Inc. (CAG - Free Report) . Inside Story Conagra expects that its unique value-over-volume strategy will help boost the company's top line in the upcoming quarters. Under this, the company ensures that its robust volume performance is not driven by price discounts but by stronger innovation, as well as new merchandising, distribution and consumer trail-related investments. (8-0)

CUSIP: 163086101